RPG Life Sciences Ltd
RPG Life Sciences Ltd is engaged in the manufacturing and marketing of Formulations (Finished Dosage Forms) and Active Pharmaceutical Ingredients (APIs) in the domestic and international market.[1]
The company is a part of RPG group which is a diversified conglomerate with interests in areas of infrastructure, tyres, information technology, pharmaceuticals, energy and plantations.[2] The group is headed by Harsh Goenka.[3]
- Market Cap ₹ 1,292 Cr.
- Current Price ₹ 781
- High / Low ₹ 1,013 / 451
- Stock P/E 21.4
- Book Value ₹ 168
- Dividend Yield 1.23 %
- ROCE 31.0 %
- ROE 21.6 %
- Face Value ₹ 8.00
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company has delivered good profit growth of 29.6% CAGR over last 5 years
- Company has been maintaining a healthy dividend payout of 27.8%
- Debtor days have improved from 47.6 to 27.4 days.
Cons
- The company has delivered a poor sales growth of 8.43% over past five years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
187 | 193 | 222 | 236 | 242 | 279 | 294 | 344 | 330 | 376 | 389 | 440 | 483 | |
154 | 175 | 206 | 224 | 228 | 256 | 274 | 306 | 296 | 315 | 318 | 353 | 388 | |
Operating Profit | 32 | 18 | 16 | 12 | 14 | 23 | 20 | 38 | 34 | 60 | 71 | 87 | 95 |
OPM % | 17% | 9% | 7% | 5% | 6% | 8% | 7% | 11% | 10% | 16% | 18% | 20% | 20% |
1 | 1 | 2 | 66 | 1 | 1 | 18 | 1 | 1 | -5 | 1 | 3 | 4 | |
Interest | 6 | 7 | 7 | 3 | 3 | 2 | 4 | 5 | 5 | 3 | 2 | 1 | 0 |
Depreciation | 10 | 10 | 10 | 11 | 11 | 10 | 11 | 14 | 15 | 16 | 16 | 16 | 15 |
Profit before tax | 17 | 2 | 1 | 65 | 1 | 12 | 23 | 20 | 15 | 36 | 54 | 73 | 84 |
Tax % | 27% | 51% | -717% | 18% | 0% | 0% | 10% | 34% | 28% | 20% | 25% | 30% | |
Net Profit | 13 | 1 | 4 | 53 | 1 | 12 | 21 | 13 | 11 | 29 | 40 | 51 | 60 |
EPS in Rs | 7.69 | 0.51 | 2.67 | 32.29 | 0.60 | 7.03 | 12.70 | 8.13 | 6.54 | 17.54 | 24.19 | 31.13 | 36.48 |
Dividend Payout % | 21% | 156% | 45% | 6% | 132% | 23% | 22% | 30% | 37% | 23% | 30% | 31% |
Compounded Sales Growth | |
---|---|
10 Years: | 9% |
5 Years: | 8% |
3 Years: | 10% |
TTM: | 15% |
Compounded Profit Growth | |
---|---|
10 Years: | 50% |
5 Years: | 30% |
3 Years: | 67% |
TTM: | 23% |
Stock Price CAGR | |
---|---|
10 Years: | 26% |
5 Years: | 9% |
3 Years: | 34% |
1 Year: | 31% |
Return on Equity | |
---|---|
10 Years: | 12% |
5 Years: | 16% |
3 Years: | 21% |
Last Year: | 22% |
Balance Sheet
Figures in Rs. Crores
Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Sep 2022 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | |
Reserves | 62 | 61 | 63 | 113 | 112 | 120 | 134 | 142 | 147 | 163 | 203 | 243 | 265 |
53 | 54 | 63 | 15 | 33 | 23 | 45 | 54 | 36 | 12 | 2 | 1 | 0 | |
62 | 54 | 67 | 56 | 39 | 49 | 55 | 82 | 54 | 78 | 85 | 88 | 96 | |
Total Liabilities | 189 | 183 | 206 | 196 | 197 | 205 | 247 | 291 | 251 | 267 | 303 | 345 | 374 |
112 | 109 | 103 | 106 | 105 | 109 | 137 | 131 | 128 | 123 | 113 | 104 | 107 | |
CWIP | 0 | 1 | 1 | 1 | 1 | 2 | 2 | 9 | 17 | 10 | 12 | 31 | 28 |
Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 17 |
77 | 73 | 102 | 89 | 92 | 94 | 108 | 152 | 106 | 134 | 178 | 210 | 223 | |
Total Assets | 189 | 183 | 206 | 196 | 197 | 205 | 247 | 291 | 251 | 267 | 303 | 345 | 374 |
Cash Flows
Figures in Rs. Crores
Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
14 | 16 | 12 | -6 | -2 | 33 | 7 | 15 | 46 | 50 | 58 | 65 | |
-13 | -8 | -12 | 59 | -10 | -15 | -30 | -16 | -19 | -11 | -8 | -35 | |
-2 | -8 | -0 | -54 | 12 | -18 | 23 | 0 | -26 | -39 | -10 | -14 | |
Net Cash Flow | -0 | 0 | 0 | 0 | -0 | -0 | 1 | -1 | 0 | 0 | 40 | 17 |
Ratios
Figures in Rs. Crores
Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 75 | 57 | 81 | 56 | 61 | 48 | 49 | 72 | 43 | 62 | 54 | 27 |
Inventory Days | 193 | 190 | 140 | 180 | 149 | 156 | 163 | 171 | 136 | 133 | 162 | 214 |
Days Payable | 293 | 161 | 226 | 176 | 109 | 135 | 102 | 165 | 83 | 127 | 132 | 117 |
Cash Conversion Cycle | -24 | 86 | -5 | 60 | 101 | 70 | 110 | 78 | 96 | 68 | 84 | 124 |
Working Capital Days | 34 | 39 | 46 | 51 | 76 | 54 | 50 | 62 | 53 | 46 | 53 | 47 |
ROCE % | 20% | 7% | 6% | 2% | 2% | 9% | 10% | 13% | 10% | 23% | 27% | 31% |
Documents
Announcements
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 12h
- Board Meeting Intimation for Board Meeting Intimation For Approval Of Unaudited Financial Results For The Quarter And Nine Months Ended December 31, 2022 2d
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 17 Jan
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 15 Jan
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 13 Jan
Annual reports
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2011
from nse
-
Financial Year 2010
from bse
-
Financial Year 2010
from nse
Concalls
-
Oct 2022TranscriptPPT
-
Sep 2022TranscriptPPT
-
Aug 2022TranscriptPPT
-
Apr 2022TranscriptPPT
-
Feb 2022TranscriptPPT
-
Jan 2022TranscriptPPT
-
Oct 2021TranscriptPPT
-
Aug 2021TranscriptPPT
-
Jun 2021TranscriptPPT
-
Jun 2019TranscriptPPT
-
Jun 2018TranscriptPPT
-
Nov 2017TranscriptPPT
-
Jun 2017TranscriptPPT
-
Nov 2016TranscriptPPT
-
Jun 2016TranscriptPPT
Domestic Formulations Segment (~62% of revenues)[1]
The company develops, manufactures and markets branded formulations in India & Nepal.[1] Its product portfolio includes various products which are sold under its key brands i.e. Azaron, Mofetyl, Lomitil, Arpimune, Imunotac, Serenace, etc. It launched 7 new products during FY21.
It has presence in various therapeutic segments such as nephrology, rheumatology, Oncology, Orthopaedics, Gastroenterology, and others.[2]